3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
2
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Salivary Gland Neoplasms
3
Endometrial Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
73
Nivolumab
27
atezolizumab
15
Docetaxel
10
Cyclophosphamide
10
cemiplimab
9
Ipilimumab
9
Paclitaxel
8
Interleukin-2
8
Biopsy
7
fludarabine
6
durvalumab
6
avelumab
6
Taxes
6
Specimen Handling
6
epacadostat
5
Magnetic Resonance Spectroscopy
5
Immune Checkpoint Inhibitors
5
Gemcitabine
5
Drug Therapy
5
Cisplatin
5
Carboplatin
5
spartalizumab
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
Cetuximab
4
utomilumab
3
trametinib
3
poly ICLC
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
trastuzumab deruxtecan
×
Head & Neck
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled